Plunkett Research Online: Moderna Inc

MODERNA INC (MRNA:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of .....



Moderna Inc
Ticker: MRNA
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617-714-6500
Fax: 617-583-1998
Address: 200 Technology Square
Cambridge, MA 02139 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines
Messenger RNA (mRNA)
Drug Development
Clinical Testing
Medicinal and Botanical Manufacturing
Contacts Description
Stephane BancelCEO/Director
James MockCFO/Chief Accounting Officer
See More
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of .....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202220212020201920182017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors:

Moderna offers its employees comprehensive benefits.